Compass Therapeutics (NASDAQ:CMPX) Cut to “Hold” at Leerink Partnrs

Leerink Partnrs downgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a strong-buy rating to a hold rating in a research report released on Friday morning,Zacks.com reports.

Other analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, November 11th. Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $5.00 to $4.00 in a research report on Friday. LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Monday, September 16th. Finally, Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $6.75.

Compass Therapeutics Stock Down 13.2 %

Shares of CMPX stock opened at $1.38 on Friday. The stock has a fifty day moving average of $1.75 and a 200 day moving average of $1.42. The firm has a market capitalization of $189.87 million, a price-to-earnings ratio of -3.73 and a beta of 0.92. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. Equities research analysts anticipate that Compass Therapeutics will post -0.37 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC raised its stake in Compass Therapeutics by 16.6% during the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after buying an additional 5,515 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Compass Therapeutics by 10.3% during the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after acquiring an additional 12,315 shares in the last quarter. Rovin Capital UT ADV purchased a new position in shares of Compass Therapeutics in the 3rd quarter worth about $25,000. Intech Investment Management LLC bought a new position in Compass Therapeutics in the 3rd quarter worth about $30,000. Finally, Geode Capital Management LLC boosted its stake in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.